Compare Novo Nordisk A/S (NVO) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Prudential Financial Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Prudential Financial Inc trades at $117.2 (market cap $40.97B). The key difference: Novo Nordisk A/S is far larger — about 5.4× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.75%). Which is the better fit depends on your goals.
| NVO | PRU | |
|---|---|---|
Market Cap | $220.53B | $40.97B |
Sector | Health | Financials |
52-Week High | $71.70 | $119.07 |
52-Week Low | $35.29 | $92.00 |
Enterprise Value | $239.49B | $68.03B |
Dividend Yield | 3.63% | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Prudential Financial (PRU) trades at $118.59, down 0.4% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates solid fundamentals with a P/E of 12.15, net income margin of 5.5%, and consistent earnings beats in recent quarters. Recent business developments include expanding retirement offerings and international growth initiatives, supported by strong cash flow generation of $6.27B from operations in 2025.
PRU presents a compelling value opportunity with attractive valuation metrics and steady profitability, though analyst sentiment remains cautious with 68% hold ratings. Key risks include significant investing outflows and debt levels, while catalysts include upcoming Q2 earnings and continued retirement market expansion. The stock trades above consensus price targets, suggesting limited near-term upside potential despite fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
